AbbVie Inc. (FRA:4AB)
Germany · Delayed Price · Currency is EUR | Market Cap | 352.03B |
| Revenue (ttm) | 49.67B |
| Net Income (ttm) | 3.17B |
| Shares Out | n/a |
| EPS (ttm) | 1.79 |
| PE Ratio | 111.04 |
| Forward PE | 19.75 |
| Dividend | 5.86 (3.00%) |
| Ex-Dividend Date | Oct 15, 2025 |
| Volume | 40 |
| Average Volume | 146 |
| Open | 192.20 |
| Previous Close | 194.60 |
| Day's Range | 192.20 - 195.40 |
| 52-Week Range | 147.00 - 209.50 |
| Beta | n/a |
| RSI | 57.92 |
| Earnings Date | Oct 29, 2025 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial numbers in USD Financial StatementsNews
AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition
Raymond James Raises AbbVie (ABBV) Price Target to $250 | ABBV Stock News
Raymond James Raises AbbVie (ABBV) Price Target to $250 | ABBV Stock News
AbbVie (ABBV) Advances in Depression Treatment with Bretisilocin Acquisition
AbbVie (ABBV) Advances in Depression Treatment with Bretisilocin Acquisition
Novo taps U.S. pharma veteran from AbbVie amid drug pricing scrutiny
Novo Nordisk (NVO) stock is in focus as the company hires an executive from AbbVie (ABBV) as head of Corporate Affairs amid U.S. drug pricing scrutiny. Read more here.
AbbVie (ABBV) Finalizes Acquisition of Bretisilocin, a Novel Antidepressant
AbbVie (ABBV) Finalizes Acquisition of Bretisilocin, a Novel Antidepressant
AbbVie finishes acquisition of depression asset bretisilocin from Gilgamesh
AbbVie acquires bretisilocin, a promising phase 2 psychedelic depression treatment. Read more here.
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). NORT...
AbbVie (ABBV) Faces Legal Challenge Amid Stock Recovery
AbbVie (ABBV) Faces Legal Challenge Amid Stock Recovery
AbbVie ends in green six straight sessions of declines
Guru Fundamental Report for ABBV
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim v...
AbbVie's Bretisilocin Hit With Enveric IP Claim
AbbVie's Bretisilocin Hit With Enveric IP Claim
Enveric Biosciences (ENVB) Pursues Legal Action Against AbbVie
Enveric Biosciences (ENVB) Pursues Legal Action Against AbbVie
AbbVie could face patent battle over depression asset gained in Gilgamesh deal
Enveric Biosciences challenges AbbVie on patent rights over a depression candidate, bretisilocin. Read more here.
AbbVie (ABBV) Pursues Acquisition Amid Patent Dispute Over Bretisilocin
AbbVie (ABBV) Pursues Acquisition Amid Patent Dispute Over Bretisilocin
Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?
ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.
JEPI, ABBV, JNJ, ROST: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the JPMorgan Equity Premium Income ETF (Symbol: JEPI) where we have detect...
Amazon, AbbVie, Datadog And A Financial Stock: CNBC's 'Final Trades'
On CNBC's “ Halftime Report Final Trades ,” on Monday, Jim Lebenthal , partner at Cerity Partners, said AbbVie Inc (NYSE: ABBV) has gained 30% this year. The stock has a good dividend yield and also ...
If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today
AbbVie (NYSE: ABBV) has outperformed the market over the past 10 years by 2.87% on an annualized basis producing an average annual return of 15.43%. Currently, AbbVie has a market capitalization of $...
Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending
The Investment Committee give you their top stocks to watch for the second half.
ClearBridge Value Strategy adds AMZN, TSM, CRM, exits INTC, ABBV, EXPE among Q3 moves
Discover how the ClearBridge Value Strategy outperformed its benchmark in Q2, key sector moves, and insights into gold and health care trends.
AbbVie Gets FDA Approval To Expand RINVOQ Use For Ulcerative Colitis And Crohn's Disease
(RTTNews) - AbbVie (ABBV) Monday announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ (upadacit...
Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending
The Investment Committee give you their top stocks to watch for the second half.
FDA Expands AbbVie's Rinvoq (ABBV) Indication for Colitis and Crohn's
FDA Expands AbbVie's Rinvoq (ABBV) Indication for Colitis and Crohn's
FDA Expands AbbVie's (ABBV) RINVOQ Approval for Ulcerative Colitis and Crohn's Disease
FDA Expands AbbVie's (ABBV) RINVOQ Approval for Ulcerative Colitis and Crohn's Disease